Logo

Henlius and Accord's Zercepac (trastuzumab- biosimilar) Receive the EMA Approval for HER2-Positive Breast Cancer and Gastric Cancer

Share this

Henlius and Accord's Zercepac (trastuzumab- biosimilar) Receive the EMA Approval for HER2-Positive Breast Cancer and Gastric Cancer

Shots:

  • The approval is based on comparative quality studies- clinical studies including preclinical data and resulted in bio-similarity- comparable efficacy and safety of Zercepac (HLX02) vs Herceptin
  • Zercepac is developed under NMPA and EMA biosimilar guidelines and has been evaluated with the reference trastuzumab including comparative quality studies- preclinical studies- a P-I clinical study and a global multi-center P-III clinical study
  • Zercepac is a novel China-mAb approved in the EU for the treatment of HER2+ early breast cancer- HER2+ metastatic breast cancer- and HER2+ metastatic gastric cancer with an expected launch in China in 2020 while its manufacturing site has received EU GMP certificates

Ref: Henlius | Image: Behance

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions